Table 2

Tumor EGFr saturation studies

Acc no.EGFr saturation status (%)
EGFr saturation by IHCaTyrosine kinase activity unboundEGFr/C225 complex
Pre tx24 h post 1st tx24 h pre 3rd txPre tx24 h post 1st tx24 h pre 3rd txPre tx24 h post 1st tx24 h pre 3rd tx
101259b100600+c+++++
207632bNDNDNDNDNDND
305310b10000NDNDND
403345NDNDNDNDNDND
502625100200++++
7076361007060+++
803995NDNDNDddd
905779NDNDND++++
120NDNDNDNDND+++
  • a IHC, immunohistochemistry; tx, therapy; ND, not done or could not be evaluated.

  • b Biopsies obtained 48 h after third dose of C225.

  • c +, ++, +++, weak, moderate, and strong band of EGFr/C225 complex, respectively; −, no EGFr/C225 complex formation.

  • d Tissue samples from Acc no. 8 may have undergone tumor necrosis and/or proteolysis.